Upcoming Webinar: Utility of PET/CT for Melanoma
Presenter: Robert S. Bridwell, MD, MBA
Medical Advisor to SOFIE
Dr. Robert Bridwell, medical advisor to SOFIE, and co-founder of PETLinQ, is a board-certified physician in both Internal Medicine and Nuclear Medicine. He has extensive knowledge and experience in continuous quality improvement programs for PET and PET/CT imaging, utilizing physician empowerment training, protocol development assistance, and quality assurance guidelines. In the last five years, Dr. Bridwell has been invited to make numerous presentations, which have included more than 1200 hours of CME credit delivered to more than 350 institutions, 100 professional society meetings and more than 150 radiology groups throughout the United States, Canada and Europe.
Date: August 14, 2018 Time: 3:00pm EDT
Who should attend? PET Interpreters, Technologists, Referring Physicians, Marketers
In this session, Dr. Bridwell will:
Detail the key aspects of the disease, including incidence, risk factors, signs/symptoms, management, conventional diagnosis and treatment
Discuss the role of FDG PET/CT in malignant melanoma, particularly in staging high risk patients.
Review the scanning protocols for this diagnostic test, including the advantages it offers in comparison to conventional imaging in detecting metastatic disease.
Outline the utility of PET/CT in response assessment and restaging for melanoma patients, as well as the limitations and challenges inherent in this modality.